Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Chordoma Vaccine vs Radiation in Unresectable Chordoma
NCT03647423Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- Fc-Fusion Proteins, Cancer Vaccines, Gene Editing
- Countries
- 1
01
Overview
A Phase 2 trial of aldoxorubicin, nogapendekin alfa inbakicept, ETBX-051, ETBX-061, gi-6301 in chordoma, sponsored by ImmunityBio, Inc.. Planned start Aug 2018; status: withdrawn.
02
Drugs
aldoxorubicinnogapendekin alfa inbakiceptETBX-051ETBX-061gi-6301
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT03647423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647423.